We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stimulating Brain Cells Using Optogenetics Stops Binge Drinking

By LabMedica International staff writers
Posted on 20 Jan 2014
Researchers are using a new strategy to change alcohol-drinking behavior in lab rats, using new optogenetic technology that uses light to stimulate neurons.

These findings could lead to effective new ways to treat alcoholism, and neurologic and mental disorders and other addictions; it also helps clarify the underlying neurochemical basis of drug addiction.

The investigators, from the University at Buffalo (NY, USA), published their findings November 2013 in the journal Frontiers in Neuroscience, are the first to show a causal relationship between the release of dopamine in the brain and drinking behaviors of animals. More...
This type of technology, which makes it possible to map the neuronal circuits responsible for specific behaviors, is a key focus of US President Obama’s Brain Research for Advancing Innovative Neurotechnologies (BRAIN) initiative.

In the research, lab rats were trained to drink alcohol in a way that mimics human binge-drinking behavior. First author Caroline E. Bass, PhD, assistant professor of pharmacology and toxicology in the UB School of Medicine and Biomedical Sciences clarified, “By stimulating certain dopamine neurons in a precise pattern, resulting in low but prolonged levels of dopamine release, we could prevent the rats from binging. The rats just flat out stopped drinking.”

Dr. Bass’s coauthors were from Wake Forest University (Winston-Salem, NC, USA), where she worked previously. Remarkably, the rodents continued to avoid alcohol even after the stimulation of neurons ended, she noted. “For decades, we have observed that particular brain regions light up or become more active in an alcoholic when he or she drinks or looks at pictures of people drinking, for example, but we didn’t know if those changes in brain activity actually governed the alcoholic’s behavior,” said Dr. Bass.

The researchers activated the dopamine neurons through a type of deep brain stimulation, but unlike techniques now used to treat certain neurologic disorders, such as severe tremors in Parkinson’s disease patients, this new technique, called optogenetics, uses light instead of electricity to stimulate neurons. “Electrical stimulation doesn’t discriminate,” Dr. Bass explained. “It hits all the neurons, but the brain has many different kinds of neurons, with different neurotransmitters and different functions. Optogenetics allows you to stimulate only one type of neuron at a time.”

Dr. Bass’ research is focused on using viral vectors to examine the brain in substance abuse. In this study, she used a virus to introduce a gene encoding a light-responsive protein into the rats’ brains. That protein then triggered a specific subpopulation of dopamine neurons in the brain’s reward system. “I created a virus that will make this protein only in dopaminergic neurons,” Dr. Bass stated.

The neuronal pathways affected in this study are involved in many neurologic disorders, she says. For that reason, the findings have relevance not only in better determining and treating alcohol-drinking behaviors in humans, but also in many debilitating mental disorders and neurologic diseases that have a dopamine component.

Dr. Bass noted that this ability to target genes to dopamine neurons could potentially lead to the use of gene therapy in the brain to diminish many of these disorders. “We can target dopamine neurons in a part of the brain called the nigrostriatal pathway, which is what degenerates in Parkinson’s disease,” she said. “If we could infuse a viral vector into that part of the brain, we could target potentially therapeutic genes to the dopamine neurons involved in Parkinson’s. And by infusing the virus into other areas of the brain, we could potentially deliver therapeutic genes to treat other neurological diseases and mental illnesses, including schizophrenia and depression.”

Related Links:

University at Buffalo
Wake Forest University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Research team leader Professor Klaus Gerwert and study lead author Dr. Grischa Gerwert in a betaSENSE laboratory (Photo courtesy of Dennis Yenmez/Stadt Bochum)

Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.